Novartis Pharma AG: Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic

Related Keywords

United States ,Americans ,America ,American ,Isabella Zinck ,Susanne Schaffert ,Rachel Levine ,Oliver Sartor ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Jamie Bearse ,Alina Levchuk ,Global Communications ,Twitter ,Accelerator Applications United States Inc ,Drug Administration ,Tulane Cancer Center ,Novartis Us External Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,European Medicines Agency ,American Cancer Society ,Medical Director ,Tulane Cancer ,Advanced Accelerator Applications ,Prescribing Information ,Phenotypic Precision Medicine ,Advanced Prostate ,Prostate Cancer ,Accelerator Applications ,Positron Emission ,Single Photon Emission Computed Tomography ,Advanced Accelerator Applications United States ,Nucl Med ,Dharma ,Luvictotm ,Approved ,First ,Argeted ,Adioligand ,Therapy ,Treatment ,Progressive ,Visma ,Positive ,Metastatic ,Castration ,Resistant ,Prostate ,Dancer ,